5月31日，三孩生育政策的“出爐”后，輔助生殖技術(shù)又成為了討論熱門！業(yè)內(nèi)分析認(rèn)為，三孩生育政策放開有望帶來(lái)更多傳統(tǒng)意義上的高齡孕齡人群加入到備孕大軍中，從而為輔助生殖行業(yè)帶來(lái)更多需求。

       生育率下滑的主要原因有育齡婦女人數(shù)減少、生育時(shí)間推遲和生育養(yǎng)育成本提高等，同時(shí)體現(xiàn)的數(shù)據(jù)還有女性的平均生育年齡一延再延。從生理上看，生育時(shí)間的推遲，會(huì)提升不孕不育的概率，從而提升輔助生殖行業(yè)的需求。

       輔助生殖指采用醫(yī)療輔助手段幫助不孕不育夫婦妊娠，其中包括人工授精、配子移植、試管嬰兒等。但這些治療技術(shù)可能都面臨著反復(fù)的試驗(yàn)，接受治療的群體常常要經(jīng)受較為艱辛的療程。大家熟知的演員張庭自爆自己做了9次試管嬰兒，扎了成百上千針，才辛苦誕下孩子。

       還有一些患者，自身可能并不具備接受試管嬰兒的治療條件，比如子宮內(nèi)膜至少需要在6-7mm厚時(shí)才能夠具備試管嬰兒的胚胎生長(zhǎng)條件。但一些患者可能會(huì)因原發(fā)（先天功能不完整）或繼發(fā)性（接受過(guò)刮宮或者因?yàn)檠装Y導(dǎo)致內(nèi)膜病變有瘡疤甚至粘連）的病變導(dǎo)致子宮內(nèi)環(huán)境不適宜胚胎發(fā)育，此時(shí)就需要進(jìn)行治療干預(yù)。

       原發(fā)或繼發(fā)性不孕或者反復(fù)的試管嬰兒失敗、更年期綜合征等都在干細(xì)胞治療不孕不育的適應(yīng)癥范圍內(nèi)，之前就有央視等媒體對(duì)此進(jìn)行過(guò)報(bào)道。

       干細(xì)胞的來(lái)源主要有以下幾種：

       圍產(chǎn)期干細(xì)胞

       自體骨髓干細(xì)胞

       自體子宮內(nèi)膜干細(xì)胞

       自體脂肪干細(xì)胞

       自體外周血造血干細(xì)胞

       這幾種來(lái)源的干細(xì)胞各有各的優(yōu)勢(shì)，圍產(chǎn)期干細(xì)胞包括臍帶間充質(zhì)干細(xì)胞和胎盤羊膜或蛻膜間充質(zhì)干細(xì)胞，它的特點(diǎn)是分化能力強(qiáng)，可增殖培育的空間更大，更為純凈。而另外幾種自體來(lái)源的干細(xì)胞，尤其是脂肪干細(xì)胞或外周血造血干細(xì)胞，具有數(shù)量充足，采集受時(shí)間限制小，無(wú)排斥反應(yīng)等特點(diǎn)。

       干細(xì)胞治療不孕不育的作用機(jī)制：

       1.干細(xì)胞具有歸巢效應(yīng)，可以準(zhǔn)確到達(dá)受損部位。

       2.干細(xì)胞再生分化能力，可以促進(jìn)卵巢組織或子宮內(nèi)膜等受損部位修復(fù)。

       3.旁分泌機(jī)制，分泌干細(xì)胞生長(zhǎng)因子等物質(zhì)，調(diào)節(jié)微環(huán)境，抑制細(xì)胞凋亡。

       干細(xì)胞的臨床應(yīng)用不僅可以用于修復(fù)子宮內(nèi)膜，還可以直接作用于卵巢。早在2018年，我國(guó)迎來(lái)了干細(xì)胞治療卵巢早衰臨床試驗(yàn)誕生的首個(gè)健康寶寶。

       據(jù)興業(yè)證券測(cè)算，我國(guó)輔助生殖市場(chǎng)發(fā)展前景廣闊。國(guó)內(nèi)目前有約4880萬(wàn)對(duì)不孕不育夫婦。隨著人們對(duì)不孕不育的治療態(tài)度越來(lái)越積極，以及消費(fèi)理念的升級(jí)。未來(lái)國(guó)內(nèi)輔助生殖市場(chǎng)前景廣闊，預(yù)計(jì)未來(lái)5年將以11.2%年復(fù)合增速快速增長(zhǎng)。相信干細(xì)胞治療不孕不育等新的技術(shù)可以更好更快的幫助解決渴望子女家庭的生育痛點(diǎn)。

　　識(shí)別二維碼，進(jìn)入H5，了解更多詳情。

參考文獻(xiàn)：

[1] Laml T, Schulz-Lobmeyr I, Obruca A, et al.Premature ovarian failure:etiology and prospects[J].Gynecol Endocrinol, 2000, 14 (4) :292-302.
[2] Gallagher JC.Effect of early menopause on bone mineral density and fractures[J].Menopause, 2007, 14 (3 pt 2) :567-571.
[3] Nippita TA, Baber RJ.Premature ovarian failure:a review[J].Climacteric, 2007, 10 (1) :11-22.
[4] 李惠敏,李海波.間質(zhì)干細(xì)胞移植治療卵巢早衰的研究進(jìn)展[J].現(xiàn)代婦產(chǎn)科進(jìn)展,2013,22(3)：237-240.
[5] 吳世凱,丁長(zhǎng)才,柏蕓,等.成體干細(xì)胞臨床應(yīng)用[J]．現(xiàn)代生物醫(yī)學(xué)進(jìn)展,2010,10(14):2763-2767.
[6] Pittenger MF,Martin BJ.Mesenchymal stem cells and their poten-tial as cardiac therapeutics[J]. Circ Res,2004,95(1):9-20.
[7] Kern S, Eichler H, Stoeve J, et al.Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue[J].Stem Cells, 2006, 24 (5) :1294-1301.
[8] Research Progress of Stem Cells in the Treatment of Premature Ovarian Failure 《國(guó)際婦產(chǎn)科學(xué)雜志》2014年41卷1期 25-28頁(yè).
[9] Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits.
[10] 孫敏.脂肪干細(xì)胞治療小鼠卵巢早衰的初步研究[D].第四軍醫(yī)大學(xué), 2014.
[11] Preclinical Research Advance in Mesenchymal Stem Cell Therapy for Premature Ovarian Failure.
[12] 干細(xì)胞水凝膠治療婦女卵巢早衰.（科技日?qǐng)?bào)2018-01-12).
[13] 人羊水來(lái)源干細(xì)胞治療大鼠卵巢早衰的初步研究。李潔，張建芳，白璐，陳必良《現(xiàn)代婦產(chǎn)科進(jìn)展》 , 2012 , 21 (2)
[14] Lai D, Wang F, Chen Y.Human amniotic fluid stem cells have a potential to recover ovarian function in mice with chemotherapy-induced sterility[J].BMC Dev Biol, 2013, 13 (1) 
[15] 臍帶間充質(zhì)干細(xì)胞移植治療卵巢早衰的實(shí)驗(yàn)研究.作者：呂曉丹.《北京協(xié)和醫(yī)學(xué)院》,2016
[16] 陳子江, 田秦杰, 喬杰, 等. 早發(fā)性卵巢功能不全的臨床診療中國(guó)專家共識(shí)[J]. 中華婦產(chǎn)科雜志, 2017, 52(9): 577-581. DOI: 10.3760/cma.j.issn.0529-567x.2017.09.001.
ChenZJ, TianQJ, QiaoJ, et al. Consensus of Chinese experts on the clinical diagnosis and treatment of premature ovarian insufficiency[J]. Chin J Obstet Gynecol, 2017, 52(9): 577-581. DOI: 10.3760/cma.j.issn.0529-567x.2017.09.001.
[17] SheikhansariG, Aghebati-MalekiL, NouriM, et al. Current approaches for the treatment of premature ovarian failure with stem cell therapy[J]. Biomed Pharmacother, 2018, 102: 254-262. DOI: 10.1016/j.biopha.2018.03.056.
[18] ZhangH, LuoQ, LuX, et al. Effects of hPMSCs on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice[J]. Stem Cell Res Ther, 2018, 9(1): 20. DOI: 10.1186/s13287-017-0745-5.315. DOI: 10.1016/j.cell.2005.06.031.
[19] NieX, DaiY, ZhengY, et al. Establishment of a mouse model of premature ovarian failure using consecutive superovulation[J]. Cell Physiol Biochem, 2018, 51(5): 2341-2358. DOI: 10.1159/000495895.
[20] JohnsonJ, BagleyJ, Skaznik-WikielM, et al. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood[J]. Cell, 2005, 122(2): 303-315. DOI: 10.1016/j.cell.2005.06.031.
[21] LeeH, SelesniemiK, NiikuraY, et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure[J]. J Clin Oncol, 2007, 25(22): 3198-3204. DOI: 10.1200/JCO.2006.10.3028.
[22] AhmadianS, MahdipourM, PazhangM, et al. Effectiveness of stem cell therapy in treatment of ovarian disorders and female infertility: a systematic review[J]. Curr Stem Cell Res Ther, 2020, 15(2): 173-186. DOI: 10.2174/1574888X14666191119122159.
[23] HuangB, QianC, DingC, et al. Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1[J]. Stem Cell Res Ther, 2019, 10(1): 362. DOI: 10.1186/s13287-019-1490-8.
[24] LingL, FengX, WeiT, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism[J]. Stem Cell Res Ther, 2019, 10(1): 46. DOI: 10.1186/s13287-019-1136-x.
[25] DingC, ZouQ, WangF, et al. Human amniotic mesenchymal stem cells improve ovarian function in natural aging through secreting hepatocyte growth factor and epidermal growth factor[J]. Stem Cell Res Ther, 2018, 9(1): 55. DOI: 10.1186/s13287-018-0781-9.
[26] HuangB, LuJ, DingC, et al. Exosomes derived from human adipose mesenchymal stem cells improve ovary function of premature ovarian insufficiency by targeting SMAD[J]. Stem Cell Res Ther, 2018, 9(1): 216. DOI: 10.1186/s13287-018-0953-7.
[27] ZhuS, HuH, XuH, et al. Human umbilical cord mesenchymal stem cell transplantation restores damaged ovaries[J]. J Cell Mol Med, 2015, 19(9): 2108-2117. DOI: 10.1111/jcmm.12571.
[28] LiuJ, ZhangH, ZhangY, et al. Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats[J]. Mol Cells, 2014, 37(12): 865-872. DOI: 10.14348/molcells.2014.0145.
[29] Abd-AllahSH, ShalabySM, PashaHF, et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits[J]. Cytotherapy, 2013, 15(1): 64-75. DOI: 10.1016/j.jcyt.2012.08.001.
[30] FuX, HeY, XieC, et al. Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage[J]. Cytotherapy, 2008, 10(4): 353-363. DOI: 10.1080/14653240802035926.